Mathematical Modeling of Drug Resistance Evolution and The Optimal Treatment Strategy in EGFR Mutated Lung Cancer
Mathematical Modeling of Drug Resistance Evolution and The Optimal Treatment Strategy in EGFR Mutated Lung Cancer
批准号:
22KJ0768
负责人:
Yu Qian
金额:
$1.09万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for JSPS Fellows
财政年份:
2023
资助国家:
日本
项目状态:
已结题
起止时间:
2023-03-08 至 2024-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In 2022, I followed my research plan and made some progress. My research is about using a mathematical model to simulate tumor progression in different therapies and predict the optimal treatment strategies for patients. Firstly, in order to get the data for model simulation, I established two types of EGFR mutation cells and co-culture them. In this experiment, I observed that drug-sensitive cells survived in drugs even with only 10% existence of drug-resistant cells. Also, this kind of co-culture response is different from different drugs, we may explore the mechanism of this phenomenon in the future. Secondly, I simulated the time course of tumor progression in different therapy strategies and analyzed the influence effect of drug-resistance cells on drug-sensitive cells through computational simulation. In this theoretical analysis, results indicated that although all-drug-resistant cells are expected to be the strongest support for helping all-drug-sensitive cells to survive because they resistant all therapy drugs, but actually it does not. Out of expectation, secondary mutation cells, which are one-drug-resistant cells, help the survivor of all-drug-sensitive cells more than all-drug-resistant cells. This might because the growth of all-drug-resistant cells is slower compared with one-drug-resistant cells in the corresponding drugs, which means all-drug-resistant cells may spend more “effort” in “self-survivor”. We would like to research its mechanism in the future, too.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金